This prospective, double blind, and randomised trial aimed to study if supplementation with the probiotic Lactobacillus reuteri could affect functional abdominal pain (FAP). Children aged 6–16 years were screened for FAP as defined in the Rome III criteria and 60 patients were recruited whereof 56 completed the study. The children were randomly allocated to receive either L. reuteri DSM 17938 (2×108 CFU/day in an oil suspension) or identical placebo for 4 weeks followed by a 4-week follow-up period without supplementation. Frequency and intensity of pain was self-recorded by the subjects.
Pain intensity decreased significantly during the 8 weeks in the L. reuteri group (p<0.001)but not in the placebo group (p>0.05) and was significantly lower than placebo at both 4 and 8 weeks
Pain frequency decreased significantly with time during the 8 weeks in both groups (p<0.05).
Conclusion: Supplementation with L. reuteri reduced perceived abdominal pain intensity, and this effect was sustained also in the follow-up period when no probiotic was ingested.
Romano C, Ferrau' V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50(10): E68-E71.